Skip to content
drillr.ai

VOR

Vor Biopharma Inc.

NASDAQ · USHealthcareBiotechnology
$17.45-3.54%

Price as of Jul 20, 2026

VOR news

Vor Biopharma Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Vor Bio Appoints David Zaccardelli to Board of Directors

    BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. “We are excited to welcome David to the Board of Dir

    Globe Newswire ·

  2. Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hired employees. The foreg

    Globe Newswire ·

  3. Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

    First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases,

    Globe Newswire ·

  4. Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

    First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331

    Globe Newswire ·

  5. Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune

    Globe Newswire ·

  6. Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 46,235 shares of Vor Bio’s common stock to 8 newly h

    Globe Newswire ·